Alembic Ltd
Alembic Limited is engaged in the businesses of Pharmaceuticals, Real Estate, and Power Assets. The company was started in 1907 as the flagship company of the Alembic Group. In 2010, the company demerged its core pharmaceutical business (formulations) into a wholly-owned subsidiary, Alembic Pharma Ltd and after the demerger, APL became the flagship company of the Alembic Group.
With its registered office in Vadodra, Alembic Ltd currently holds a 28.41% stake in Alembic Pharma Ltd and a 19.01% stake in another group entity Paushak Limited.[1]
- Market Cap ₹ 2,143 Cr.
- Current Price ₹ 83.4
- High / Low ₹ 108 / 56.3
- Stock P/E 24.6
- Book Value ₹ 32.8
- Dividend Yield 2.64 %
- ROCE 10.2 %
- ROE 9.45 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 54.6%
Cons
- Stock is trading at 2.55 times its book value
- Tax rate seems low
- Company has a low return on equity of 7.18% over last 3 years.
- Earnings include an other income of Rs.44.0 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Realty Industry: Construction
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
121 | 179 | 154 | 144 | 134 | 147 | 125 | 124 | 74 | 72 | 76 | 123 | 141 | |
122 | 164 | 126 | 134 | 128 | 140 | 114 | 106 | 70 | 62 | 63 | 85 | 95 | |
Operating Profit | -1 | 16 | 28 | 10 | 6 | 7 | 11 | 18 | 4 | 11 | 13 | 38 | 46 |
OPM % | -1% | 9% | 18% | 7% | 5% | 5% | 9% | 15% | 5% | 15% | 17% | 31% | 32% |
4 | 10 | 18 | 21 | 25 | 25 | 37 | 29 | 93 | 10 | 89 | 54 | 44 | |
Interest | 5 | 5 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 11 | 10 | 8 | 6 | 6 | 5 | 4 | 3 | 3 | 4 | 4 | 6 | 8 |
Profit before tax | -14 | 11 | 33 | 23 | 25 | 27 | 44 | 45 | 94 | 17 | 97 | 85 | 82 |
Tax % | 10% | -4% | 12% | -3% | 2% | -3% | 5% | 8% | 0% | 19% | 12% | 7% | |
-12 | 11 | 30 | 24 | 25 | 27 | 42 | 41 | 94 | 13 | 86 | 79 | 76 | |
EPS in Rs | -0.46 | 0.43 | 1.11 | 0.90 | 0.93 | 1.03 | 1.56 | 1.60 | 3.64 | 0.52 | 3.34 | 3.09 | 2.98 |
Dividend Payout % | -0% | 23% | 14% | 17% | 16% | 19% | 13% | 12% | 16% | 38% | 54% | 71% |
Compounded Sales Growth | |
---|---|
10 Years: | -4% |
5 Years: | 0% |
3 Years: | 19% |
TTM: | 35% |
Compounded Profit Growth | |
---|---|
10 Years: | 22% |
5 Years: | 18% |
3 Years: | -2% |
TTM: | 9% |
Stock Price CAGR | |
---|---|
10 Years: | 20% |
5 Years: | 20% |
3 Years: | -6% |
1 Year: | 48% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 9% |
3 Years: | 7% |
Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 27 | 27 | 53 | 53 | 53 | 53 | 53 | 51 | 51 | 51 | 51 | 51 | 51 |
Reserves | 170 | 179 | 177 | 211 | 295 | 314 | 395 | 361 | 432 | 775 | 962 | 778 | 790 |
103 | 25 | 22 | -0 | 9 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | 5 | |
91 | 113 | 104 | 91 | 64 | 81 | 73 | 57 | 51 | 109 | 130 | 119 | 139 | |
Total Liabilities | 391 | 344 | 356 | 356 | 421 | 449 | 522 | 470 | 534 | 936 | 1,144 | 948 | 986 |
195 | 185 | 178 | 169 | 146 | 171 | 179 | 209 | 225 | 261 | 294 | 318 | 341 | |
CWIP | 0 | 3 | 2 | 2 | -0 | 0 | -0 | -0 | 3 | 6 | 0 | 0 | 1 |
Investments | 23 | 23 | 21 | 35 | 150 | 189 | 276 | 205 | 197 | 581 | 726 | 503 | 472 |
173 | 132 | 155 | 149 | 124 | 89 | 67 | 55 | 109 | 88 | 124 | 127 | 172 | |
Total Assets | 391 | 344 | 356 | 356 | 421 | 449 | 522 | 470 | 534 | 936 | 1,144 | 948 | 986 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-59 | 80 | -10 | 22 | 10 | 52 | 24 | 22 | 5 | -1 | -22 | 35 | |
-5 | 12 | 18 | 5 | -5 | -47 | -23 | 68 | 57 | -35 | 23 | 11 | |
65 | -94 | -8 | -25 | -5 | -5 | -3 | -89 | -6 | -15 | -6 | -46 | |
Net Cash Flow | 0 | -2 | -0 | 2 | -0 | -0 | -2 | 1 | 56 | -52 | -5 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 48 | 37 | 66 | 122 | 76 | 54 | 74 | 40 | 44 | 66 | 72 | 67 |
Inventory Days | 646 | 351 | 1,924 | 880 | 659 | 438 | 247 | 289 | 411 | 2,112 | 2,885 | 5,118 |
Days Payable | 176 | 173 | 659 | 200 | 144 | 128 | 125 | 202 | 151 | 675 | 635 | 993 |
Cash Conversion Cycle | 518 | 215 | 1,330 | 801 | 591 | 364 | 195 | 126 | 304 | 1,504 | 2,322 | 4,191 |
Working Capital Days | 324 | 93 | 200 | 235 | 172 | 39 | 20 | 13 | 28 | 98 | 231 | 127 |
ROCE % | -2% | 6% | 16% | 9% | 8% | 8% | 10% | 10% | 21% | 2% | 10% | 10% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 17h
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
- Closure of Trading Window 1d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 21 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 18 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
Business Portfolio:
A) Pharmaceuticals:
The company deals in the bulk drugs manufacturing and marketing of APIs like Estolate, Biphenyl Valine Oxalate, Venlafaxine, etc. AL is also engaged in R&D activity. [1]